Corporate VCs Yield Better Innovation Outcomes

Headshot of a person with short hair and glasses, wearing a suit and shirt, smiling in front of a blurred window background.

Recent research by Senior Fellow Gary Dushnitsky measures the innovation success of new biotech ventures by tracking their patenting and publishing rates. He and coauthor Elisa Alvarez-Garrido find that the identity of the investor makes a big difference.Read More

Are Entrepreneurial Ventures’ Innovation Rates Sensitive to Investor Complementary Assets?

Published Research

Entrepreneurial ventures are a key source of innovation. Nowadays, ventures are backed by a wide array of investors whose complementary asset profiles differ significantly. We therefore assert that entrepreneurial ventures can no longer be studied as a homogeneous group.Read More

Publications and Patents in Corporate Venture-Backed Biotech

Published Research

Biotech startups increasingly turn to corporate venture capital (VC) arms for funding, rather than to traditional venture capitalists. The innovation implications for these startups remain unexplored. Here, we present evidence that the shift in funding patterns is associated with a greater output of scientific publications as well as patenting.Read More